INmune Bio Inc.

About INmune Bio Inc.

INmune Bio Inc. is a clinical stage biotechnology company focused on restoring function in the innate immune system to fight disease. Their pipeline includes first-in-class therapies designed to maximize benefit without compromising safety, targeting neurologic disease and certain forms of cancer.

Products & Services

XPro1595:A therapy under development, with related publications available, likely targeting neurologic diseases or related conditions.

Pipeline Therapies:Innovative treatments being developed for neurologic diseases and certain forms of cancer, focusing on patient benefit and safety.

XPro1595

INKmune

Specialties

Innate Immune System Restoration Neurologic Disease Treatment Cancer Treatment Clinical Development for Patient Benefit matching drug mechanism of action to patient biology relevant clinical trial metrics progressive trial design anchored to patient outcomes Immunotherapy Clinical development Drug mechanism matching to patient biology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 4600000 MR: - FA: $4.6M FAN: 4600000	D: 2026-07-30 FD: 2026-07-30	-
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 19000000 MR: - FA: approximately $19 million FAN: 19000000	D: 2025-06-30 FD: 2025-06-30	-
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 19000000 MR: - FA: approximately $19 million FAN: 19000000	D: 2025-06-27 FD: 2025-06-27	1 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 13000000 MR: - FA: 13.0 million FAN: 13000000	D: 2024-09-13 FD: 2024-09-13	2 investors
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 9700000 MR: - FA: $9.7 million FAN: 9700000	D: 2024-04-25 FD: 2024-04-25	1 investors
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4800000 MR: - FA: approximately $4.8 million FAN: 4800000	D: 2024-04-22 FD: 2024-04-22	1 investors
7	RT: Non-dilutive Funding (R&D Rebates) T: - FT: Non-dilutive Funding (R&D Rebates)	A: 6400000 MR: - FA: approximately $6.4 million FAN: 6400000	D: 2023-02-08 FD: 2023-02-08	2 investors

Grant Latest

2026-07-30

$4.6M

Registered Direct Offering 2025-06-30

$19.0M

Registered Direct Offering 2025-06-27

$19.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

INmune Bio Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised